ReviewIndian dermatology online journal
Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review.
Review in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 348 citations in OpenAlex.
- S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection).Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis.Archives of dermatological research · 2025Pooled it
- Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.The Journal of dermatology · 2021Trial
- Correlation ofAntimicrobial agents and chemotherapy · 2018Trial
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Oral isotretinoin for the treatment of dermatologic conditions other than acne: a case series.Dermatology reports · 2026Article
- Nanoemulsion-Based Tea Tree Oil: A New Frontier in Enhancing Clotrimazole Antifungal Activity.Molecular biotechnology · 2026Article
- Preparation and Optimization of Voriconazole Gel 0.25% for Topical Delivery in Terbinafine Resistance Dermatophytosis: In Vitro and Pilot Animal Study.Dermatology research and practice · 2026Article
- Mental Health and Quality of Life in Chronic and Recurrent vs First-Episode Dermatophytosis: A Cross-Sectional Study.Consortium psychiatricum · 2026Article
- Does the use of topical azoles have an impact on antifungal resistance?The Journal of antimicrobial chemotherapy · 2025Article
- Case Report: From Misdiagnosis to Accurate Identification: Managing a Case Series ofMicroorganisms · 2025Article
- Article
- Unlocking the Skin-Protective Effects ofAntibiotics (Basel, Switzerland) · 2025Article
- NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in Nepal.Dermatology research and practice · 2025Review
- Clinical and Microbiological Spectrum of Dermatophytosis From a Tertiary Care Institute.Cureus · 2025Article
- A Case of Superficial Mycoses in a Patient with Systemic Lupus Erythematosus.Clinical, cosmetic and investigational dermatology · 2025Article
- Lactams Exhibit Potent Antifungal Activity Against Monospecies and Multispecies Interkingdom Biofilms on a Novel Hydrogel Skin Model.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Epidemiological survey of 32,786 culture-positive dermatophytosis cases in Hangzhou from 2018 to 2023.Mycopathologia · 2024Article
- Prolonged retention of luliconazole nanofibers for topical mycotic condition: development, in vitro characterization and antifungal activity against Candida albicans.Journal of materials science. Materials in medicine · 2024Article
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of superficial mycotic infection worldwide is 20-25% of which dermatophytes are the most common agents. Recent developments in understanding the pathophysiology of dermatophytosis have confirmed the central role of cell-mediated immunity in countering these infections. Hence, a lack of delayed hypersensitivity reaction in presence of a positive immediate hypersensitivity (IH) response to trichophytin antigen points toward the chronicity of disease. Diagnosis, though essentially clinical should be confirmed by laboratory-based investigations. Several new techniques such as polymerase chain reaction (PCR) and mass spectroscopy can help to identify the different dermatophyte strains. Management involves the use of topical antifungals in limited disease, and oral therapy is usually reserved for more extensive cases. The last few years have seen a significant rise in the incidence of chronic dermatophyte infections of skin which have proven difficult to treat. However, due to the lack of updated national or international guidelines on the management of tinea corporis, cruris, and pedis, treatment with systemic antifungals is often empirical. The present review aims to revisit this important topic and will detail the recent advances in the pathophysiology and management of tinea corporis, tinea cruris, and tinea pedia while highlighting the lack of clarity of certain management issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.